We, INDIS Air have launched a new brand name G.Polpack to grow into a global company by contributing to the new market base to new airpack packaging Industry. Polpack is a brand-new concept of packaging and buffering solution by using heat fusion in an independent air pillar made of LLDPE + NYLON laminated film valve. Polpack can reduce the transportation cost and environmental use from its small volume compared to the traditional packing materials. With Polpack, the packaging process can be done with just one simple air inflation which does not occur dirt and particles. Polpack has absorbed shock better than ordinary packing materials with a more competitive price which can reduce your cost. Polpack received “Green Certification” of reducing waste in 2014. The volume can be reduced by more than 70% compared to EPS packaging materials. Polpack’s is designed to stand strong impacts and reducing movements by its cylindrical structure and perfectly fitting design. With our accumulated design technology and providing personal customized service, Polpack provides the best design and solution. Polpack is an eco-friendly packaging material used as a packaging material for agricultural / marine / livestock foods which is free from Hazardous Materials Regulations. | INDIS Air is a company that develops and manufactures innovative and creative packaging cushioning materials. Since its establishment in 2006, we have accumulated extensive experience in the air packaging industry, becoming a leader in the domestic market. INDIS Air’s flagship brand, G-polpack, ahs garnered significant attention not only in Korea but also internationally. We will continue to introduce a wide range of products with creative approaches, striving to lead the global market.INDIS Air provides innovative packaging solutions that satisfy both businesses and customers while continuously researching more eco=friendly and sustainable packaging.We are committed to developing recycled materials for the environment and constantly strive to enhance the efficiency of product packaging.
INCREX Inc.
Global No. 1 Luge Cart supplier, INCREX Korea.
Incheon Free Economic Zone Authority (IFEZ)
Incheon is leading the evolution from a smart city to an innovative AI city, addressing urban challenges for sustainable growth. At CES 2026, the INCHEON-IFEZ Booth will showcase cutting-edge solutions that realize this vision, serving as a global hub for business and advanced industries.
iN Therapeutics
## Overview ## iN Therapeutics is a clinical-stage South Korean biotechnology company dedicated to discovering and developing “First-in-Class” and “Best-in-Class” ion channel modulators. As a spin-off from Daewoong Pharmaceutical, we combine the agility of a biotech with the robust R&D infrastructure of a major pharmaceutical group. Our mission is to address significant unmet medical needs in Central Nervous System (CNS) and chronic pain disorders by delivering highly selective and safe ion channel therapies. ## Core Technology: The VITVO™ Platform ## At the heart of our innovation is VITVO™, our proprietary ion channel drug discovery platform. Historically, ion channel drug discovery has been hindered by the “efficacy-toxicity trade-off” due to poor subtype selectivity. VITVO™ overcomes this challenge through: • Proprietary Compound Library: A vast collection of ion channel-specific chemical scaffolds. • Advanced Electrophysiology: High-throughput screening (HTS) and sophisticated patching techniques that ensure high-fidelity in vitro-in vivo correlation. • Precision Targeting: Achieving unprecedented subtype selectivity (e.g., Nav1.7 vs. Nav1.5) to eliminate off-target side effects and maximize the safety margin. ## Key Pipeline Assets ## iN Therapeutics is advancing a diverse and robust pipeline of innovative therapies: 1. Aneratrigine (iN1011-N17) | Target: Nav1.7 (Non-opioid Analgesic) • Indication: Pain • Achievement: Successfully demonstrated exceptional selectivity and efficacy, leading to a $500+ million global licensing deal. This asset represents our ability to tackle high-difficulty targets and translate them into significant commercial value. 2. iN3011-K23 | Target: Kv7.2/7.3 Activator • Indication: Focal Epilepsy and Neuropathic Pain. • Competitive Edge: Unlike traditional anti-seizure medications that often cause drowsiness through GABAergic pathways, Aneratrigine offers a “Clean Profile.” It focuses solely on Kv7.2/7.3 channels, aiming for superior efficacy without the typical CNS side effects, thereby significantly improving patient quality of life. 3. iN4011-KC2 | Target: KCC2 (First-in-Class) • Indication: Epilepsies and Neurological Disorders. • Vision: Targeting the fundamental mechanism of chloride homeostasis in the brain to treat refractory neurological conditions. 4. Nav 1.2/1.6 Inhibitor | Target: Dual Selective Inhibition • Indication: Epilepsy. • Strategy: Developing highly selective inhibitors to treat genetic epilepsies while avoiding cardiac and peripheral toxicities. ## Partnership & Track Record ## We are a proven partner in the global licensing market. Our landmark $500+M deal for the Nav1.7 program highlights our excellence in asset development and alliance management. We are actively seeking strategic partnerships for our preclinical-stage assets, including Kv7.2/7.3 Activator, and are open to collaborative research opportunities utilizing our VITVO™ platform. ## Vision for BIO USA 2026 ## At BIO USA 2026, iN Therapeutics seeks to engage with global pharmaceutical leaders, investors, and research institutions to discuss licensing-out opportunities, co-development strategies, and the future of ion channel-based medicine. We invite you to explore how our “Ion Channel Frontiers” are reshaping the landscape of CNS and Pain therapy.
IMT Inc.
IMT Inc. presents NANO-i, a breakthrough in medical tech. This portable electrospinning device creates real-time nanofiber dressings for immediate hemostasis and wound protection. By spraying medical-grade nanofibers directly onto the site, NANO-i ensures a breathable, safe shield for optimal recovery without secondary infection.
Impactive Ai
ImpactiveAI is a specialized AI solutions company in demand and price forecasting. Its solution, Deepflow, accurately predicts product demand, raw material prices, and new product performance. This empowers enterprises to reduce uncertainty, optimize inventory, and strengthen procurement strategies.
ImmuneOncia Therapeutics Inc
ImmuneOncia is a clinical-stage biotech company focused on immuno-oncology established in 2016. ImmuneOncia is dedicated to delivering safe, effective, and novel immunotherapies to oncology patients worldwide. Its portfolio includes a variety of immune checkpoint antibodies such as PD-L1, CD47, LAG3 and Bi-specifics. ImmuneOncia is seeking partners for its immuno-oncology pipeline drugs as shown below. 1) IMC-002 (CD47 mAb) – Ph 1b trial for solid tumors ongoing; Superior safety and PK profile due to lack of RBC binding and less antigen sink; Open to Regional or Global (excl. China) collaboration 2) IMC-001 (PD-L1 mAb) – Ph 2 trial for Extranodal NK/T cell Lymphoma(ENKTL) completed and orphan drug designated (ODD); Ph 2 trial for TMB-H solid tumors ongoing; Open to Regional or Global collaboration 3) IMC-201 (CD47xPD-L1 bsAb) – Preliminary safety and efficacy data from in-vitro and/or in-vivo data; Open for Regional or Global collaboration
IMEDICOM Co., Ltd
IMEDICOM Co., Ltd. is a South Korea–based medical device company specializing in automated surgical systems for orthopedic procedures. With over 20 years of experience, IMEDICOM develops surgeon-focused technologies that enhance surgical precision, improve outcomes, and reduce patient risk. The company supports minimally invasive surgery through smart engineering and exports to more than 30 countries via a strong global distributor network.